RxDoctor Payments Data

Richard Ahn, MD

Neurology · Desoto, TXNPI 1700878071

Payments from drug & device makers

$16,627in general payments, 2019–2025

Across 890 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • Genentech USA, Inc.$897
  • Eisai Inc.$882
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$16,20197%
  • Education$4112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)101$1,343
Novartis70$1,276
UCB, Inc.48$1,151
Acadia Pharmaceuticals Inc52$1,059
Genentech USA, Inc.42$897
Eisai Inc.38$882
Teva Pharmaceuticals USA, Inc.34$688
SK Life Science, Inc.32$684
Pfizer32$656
Amgen(2 entities)32$635
Amneal Pharmaceuticals LLC37$597
Biogen33$528
Grifols USA, LLC26$517
Sanofi29$472
EMD Serono, Inc.25$469
Supernus Pharmaceuticals, Inc.41$334
Kyowa Kirin, Inc.14$284
AstraZeneca(2 entities)15$283
TG Therapeutics, Inc.9$256
Sunovion Pharmaceuticals Inc.18$252
MDD US Operations, LLC5$237
Corium, LLC12$228
Johnson & Johnson(2 entities)6$209
Greenwich Biosciences, Inc.9$208
Mallinckrodt Hospital Products Inc.7$189
Biohaven Pharmaceutical Holding Company Ltd.7$168
Otsuka America Pharmaceutical, Inc.16$161
GE HealthCare10$138
Abbott7$131
Sumitomo Pharma America, Inc.7$128
Lilly USA, LLC9$128
Cook Medical LLC1$123
Livanova USA, Inc.3$115
Upsher-smith Laboratories LLC5$101
Lundbeck LLC5$91
Biohaven Pharmaceuticals, Inc.6$91
Arbor Pharmaceuticals, Inc.4$71
Adamas Pharmaceuticals, Inc.4$71
Bristol Myers Squibb3$66
Argenx US, Inc.3$66
Life Molecular Imaging Ltd2$56
Boston Scientific2$54
Avion Pharmaceuticals2$42
Impel Pharmaceuticals Inc.2$38
Acorda Therapeutics, Inc2$36
Takeda Pharmaceuticals U.S.A., Inc.1$35
Hospira, Inc.3$34
Scilex Pharmaceuticals Inc.2$34
Catalyst Pharmaceuticals, Inc.2$33
Jazz Pharmaceuticals Inc.1$30
Ipsen Biopharmaceuticals, Inc1$30
Cycle Pharmaceuticals Inc1$29
Aprecia Pharmaceuticals, LLC2$29
Mallinckrodt Enterprises LLC1$29
Stryker1$23
Assertio Therapeutics, Inc.1$18
CSL Behring1$17
Bioventus LLC1$17
Neurelis, Inc.1$13
E.r. Squibb & Sons, L.L.C.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,627 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$205,526
Medicare patients
314
Services billed
954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4666$478,778
BriviactBrivaracetam73$113,762
VumerityDiroximel Fumarate13$109,624
AptiomEslicarbazepine Acetate57$103,597
Kesimpta PenOfatumumab12$98,537
Aimovig AutoinjectorErenumab-Aooe36$69,621
FycompaPerampanel42$66,148
UbrelvyUbrogepant32$45,083
NayzilamMidazolam22$44,246
QuliptaAtogepant32$38,451
Nurtec OdtRimegepant Sulfate21$38,315
Emgality PenGalcanezumab-Gnlm18$34,502
ZonisadeZonisamide14$33,009
NuedextaDextromethorphan Hbr/Quinidine15$31,813
Teriflunomide12$27,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$517$478,77866 claims
UCB, Inc.Briviact, Nayzilam$1,151$158,00995 claims
BiogenVumerity$528$109,62413 claims
Sunovion Pharmaceuticals Inc.Aptiom$252$103,59757 claims
AbbVieUbrelvy, Qulipta$1,343$83,53464 claims
Eisai Inc.Fycompa$882$66,14842 claims
PfizerNurtec Odt$656$38,31521 claims
Amneal Pharmaceuticals LLCRytary$597$19,01730 claims
Otsuka America Pharmaceutical, Inc.Rexulti$161$18,53811 claims
Kyowa Kirin, Inc.Nourianz$284$16,93811 claims
Lilly USA, LLCReyvow$128$9,06512 claims
Aprecia Pharmaceuticals, LLCSpritam$29$8,17913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →